LABD

LABD is in a Stage 4 decline with confirmed lower-highs & lower-lows. Despite evidence of capitulation exhaustion, recent upside extension above key EMAs lacks follow-through, suggesting the bearish trend persists. We defer selling until price re-tests and rejects the EMA zone or prior minor swing high, trimming into the resistance cluster on failure to reclaim.

• ↑Delivers 300% inverse daily returns, enabling amplified gains on biotech declines
• ↑Generated 88.41% return over past year post-sector correction
• ↓Decline of -60.7% YTD underscores persistent bearish trend